Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Pfizer operates as a global biopharmaceutical leader The company maintains diversified therapeutic and vaccine portfolio Market activity reflects alignment with S&P 500 Fund trends Pfizer Inc.

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...

--Currently down nine consecutive days; down 11.06% over this period --Longest losing streak since Feb. 25, 2020, when it fell for nine straight trading days --Worst nine-day stretch since the nine ...